Tot Biopharm, a private equity-backed Chinese biopharmaceutical company, has filed for an initial public offering (IPO) in Hong Kong on Monday under the rules that allow pre-profit companies to float shares on the stock exchange.
Chinese Pre-Profit Cancer Drug Developer Tot Biopharm Files For HK IPO comes originally from China Money Network. All Rights Reserved.